Literature DB >> 8632334

Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.

B J Ring1, J Catlow, T J Lindsay, T Gillespie, L K Roskos, B J Cerimele, S P Swanson, M A Hamman, S A Wrighton.   

Abstract

The formation kinetics of 2-hydroxymethyl olanzapine (2-OH olanzapine), 4'-N-oxide olanzapine (N-O olanzapine) and 4'-N-desmethyl olanzapine (NdM olanzapine) were analyzed in vitro. Biphasic kinetics were observed for formation of 2-OH and NdM olanzapine. The high-affinity enzyme responsible for 2-OH olanzapine formation by two human liver samples exhibited an intrinsic clearance (CLint) of 0.2 microliter/min/mg. NdM olanzapine formation by two human liver samples exhibited a CLint of 1.0 microliter/min/mg for the high affinity enzyme. The formation of N-O olanzapine was linear up to 300 microM olanzapine, yielding a CLint of 0.32 to 1.70 microliters/min/mg. The formation of 7-hydroxy olanzapine (7-OH olanzapine) exhibited an apparent Km of 24.2 microM. The rates of 2-OH olanzapine formation correlated with CYP2D6 levels and activity, and it was formed to the greatest extent by cDNA-expressed CYP2D6. N-O olanzapine formation correlated with human liver flavin-containing monooxygenase (FMO3) levels and activity. NdM olanzapine and 7-OH olanzapine formation correlated with CYP1A2 catalytic activities and they were formed to the greatest extent by expressed CYP1A2. These results suggest that CYP1A2 catalyzes NdM olanzapine and 7-OH olanzapine formation, CYP2D6 catalyzes 2-OH olanzapine formation and FMO3 catalyzes N-O olanzapine formation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8632334

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  34 in total

1.  Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication?

Authors:  Carole Lavigne; Jocelyn Yelle; Gilles Sauve; Alain R Thierry
Journal:  AAPS PharmSci       Date:  2002

Review 2.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

3.  Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder.

Authors:  Matthew A Seager; Vanessa N Barth; Lee A Phebus; Kurt Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

Review 4.  New atypical antipsychotics. Experience and utility in the elderly.

Authors:  R A Sweet; B G Pollock
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

Review 5.  Interactions between the cytochrome P450 system and the second-generation antipsychotics.

Authors:  Trevor I Prior; Glen B Baker
Journal:  J Psychiatry Neurosci       Date:  2003-03       Impact factor: 6.186

6.  Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.

Authors:  Janne T Backman; Marjo J Karjalainen; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

7.  The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients.

Authors:  Yan-Nan Zang; Fang Dong; An-Ning Li; Chuan-Yue Wang; Gui-Xin Guo; Qian Wang; Yan-Fang Zhang; Lei Zhang; Jose de Leon; Can-Jun Ruan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03-06       Impact factor: 2.441

8.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors.

Authors:  Satomi Nagashima; Makiko Shimizu; Hiroshi Yano; Norie Murayama; Toshio Kumai; Shinichi Kobayashi; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

Review 10.  Pharmacogenomics can improve antipsychotic treatment in schizophrenia.

Authors:  Qingqing Xu; Xi Wu; Yuyu Xiong; Qinghe Xing; Lin He; Shengying Qin
Journal:  Front Med       Date:  2013-04-21       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.